Technology | June 24, 2007

FDA Approves Drug for High Blood Pressure

June 21, 2007 - Exforge, a single-tablet combination of two of the most prescribed high blood pressure medicines, has been granted final FDA approval for use in patients who suffer from high blood pressure.

Exforge is the first medicine of its kind to combine the active ingredients of an angiotensin receptor blocker, Diovan (valsartan) and a calcium channel blocker - Norvasc (amlodipine) - with the convenience of a single, once-daily tablet.

"High blood pressure continues to be a major public health issue in the US. Many patients will require multiple medications to achieve blood pressure control," said Bertram Pitt, M.D., FACC, and a professor of Medicine Emeritus at the University of Michigan School of Medicine Division of cardiology. "This new treatment offers great efficacy and improved convenience with a single tablet that will simplify treatment for patients."

For more information: www.exforge.com


Related Content

News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
News | Pharmaceuticals

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...

Home September 05, 2025
Home
News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
Subscribe Now